<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02672709</url>
  </required_header>
  <id_info>
    <org_study_id>#15-128</org_study_id>
    <nct_id>NCT02672709</nct_id>
  </id_info>
  <brief_title>Apixaban in Hemodialysis</brief_title>
  <official_title>Pharmacokinetics and Pharmacodynamics of Apixaban in End-stage Renal Disease Patients on Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jewish General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to determine the effects of end-stage renal disease on the pharmacokinetics,
      pharmacodynamics, safety, and tolerability of apixaban. This is a single-center open-label
      pharmacological study. Apixaban will be prescribed at the dose of 2.5 mg twice per day for
      nine days. The concentration of the drug will be measured with repetitive blood tests the
      first and the eighth day of administration (non-dialysis days). The same blood tests will be
      repeated before, during, and after dialysis on dialysis days. If the study shows inadequate
      or suboptimal efficacy with the 2.5 mg dose, it will be repeated with the 5 mg twice-daily
      dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apixaban concentration</measure>
    <time_frame>Day 8</time_frame>
    <description>Examine whether apixaban accumulates after an 8-day administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Apixaban concentration before, during, and after hemodialysis</measure>
    <time_frame>Before dialysis, then every hour until the end of dialysis on day 2 and day 9</time_frame>
    <description>Apixaban levels to be measured before dialysis, then every hour until the end of dialysis on day 2 and day 9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment related adverse effects</measure>
    <time_frame>Day 1 to 9</time_frame>
    <description>Short-term treatment related adverse effects: bleeding events, allergic reactions, any other symptom reported by the patient that could be attributed to the drug</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>End-stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Anticoagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban will be prescribed at the dose of 2.5 mg twice per day for nine days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apixaban</intervention_name>
    <arm_group_label>Anticoagulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age&gt;18 years

          -  end-stage renal disease on stable hemodialysis treatment (3 weekly sessions of 4
             hours) for at least 6 months

          -  no residual kidney function

          -  non-valvular atrial fibrillation

        Exclusion Criteria:

          -  age â‰¥80 years

          -  Body mass index (BMI)&lt;21 or BMI&gt;40

          -  active bleeding

          -  high bleeding risk (HAS BLED score &gt;3)

          -  active malignancy

          -  psychiatric disorders

          -  decompensated thyroid disorders

          -  decompensated heart failure

          -  acute myocardial infarction-cerebrovascular accident-head trauma in the last 3 months

          -  previous history of venous thromboembolic disease in the last 6 months

          -  previous history of coagulopathy already treated by vitamin K antagonists (VKAs) or
             novel oral anticoagulants

          -  uncorrected rhythm or conduction disturbances

          -  dual antiplatelet therapy

          -  known liver disease or elevated transaminases &gt; 2x upper limit of normal

          -  Hemoglobin &lt; 90 g/l

          -  platelets &lt; 100,000 /ml

          -  known hypersensitivity to apixaban

          -  treatment with a potent inhibitor or inducer of the cytochrome P450 3A4 and/or
             P-glycoprotein

          -  absence of effective contraception where applicable

          -  drug or alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Verma A, Cairns JA, Mitchell LB, Macle L, Stiell IG, Gladstone D, McMurtry MS, Connolly S, Cox JL, Dorian P, Ivers N, Leblanc K, Nattel S, Healey JS; CCS Atrial Fibrillation Guidelines Committee. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol. 2014 Oct;30(10):1114-30. doi: 10.1016/j.cjca.2014.08.001. Epub 2014 Aug 13. Erratum in: Can J Cardiol. 2014 Dec;30(12):1495. Can J Cardiol. 2015 Oct;31(10):1302.</citation>
    <PMID>25262857</PMID>
  </reference>
  <reference>
    <citation>Granger CB, Chertow GM. A pint of sweat will save a gallon of blood: a call for randomized trials of anticoagulation in end-stage renal disease. Circulation. 2014 Mar 18;129(11):1190-2. doi: 10.1161/CIRCULATIONAHA.113.007549. Epub 2014 Jan 22.</citation>
    <PMID>24452751</PMID>
  </reference>
  <reference>
    <citation>Wang X, Tirucherai G, Marbury TC, Wang J, Chang M, Zhang D, Song Y, Pursley J, Boyd RA, Frost C. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016 May;56(5):628-36. doi: 10.1002/jcph.628. Epub 2015 Dec 22.</citation>
    <PMID>26331581</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2016</study_first_submitted>
  <study_first_submitted_qc>January 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2016</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jewish General Hospital</investigator_affiliation>
    <investigator_full_name>Mark L. Lipman</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Factor Xa Inhibitors</keyword>
  <keyword>Renal Dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

